On 9 June 2010, orphan designation (EU/3/10/749) was granted by the European Commission to NovImmune B.V., the Netherlands, for recombinant human anti-interferon gamma monoclonal antibody for the treatment of haemophagocytic lymphohistiocytosis.
This medicine is now known as emapalumab.
The sponsorship was transferred to Swedish Orphan Biovitrum AB (publ), Sweden, in June 2019.
Recombinant human anti-interferon gamma monoclonal antibody (emapalumab)
Treatment of haemophagocytic lymphohistiocytosis
|Date of designation||
|Orphan designation status||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see: